A Special Dialogue on Why American Investors Value Japan's Scientific Innovations

Exploring the Value of Japanese Science to American Investors

On June 30, 2026, the Hibiya Mitsui Conference in Tokyo illuminated with soft sunlight as domestic and international investors, business stakeholders, and media gathered for a noteworthy event. Nano Holdings, Inc. hosted a special dialogue titled, "Why Do U.S. Investors Value Japan?" featuring insights from Dr. Neil W. Gibson, Chairman of Nano Holdings US, LLC, and Dr. Yasunori Yamaguchi, Chief Business Development Officer of Nano Holdings, Inc. This dialogue created a platform for discussion on the appeal of the Japanese market from the perspective of U.S. investors and the significance of accessing American capital to further enhance Japan’s outstanding scientific and technological advancements.

Following the dialogue, a Q&A session was held where Dr. Gibson, along with Jun Matsumura, Chairman and CEO of Nano Holdings, and Tomo Iino, CIO, responded to numerous questions about attractive asset conditions for investors, methods for asset reconstruction, the investment scale of Nano Holdings, and future project prospects.

Key Themes from the Dialogue

During the discussions, Dr. Yamaguchi highlighted the significant contributions of Japan's top-tier scientific research and technological innovations to the global arena. He stressed that while Japan has historically enjoyed a robust market for investments, the number of deals has been on the decline since 2021, overshadowed by China's rapid growth in both cost efficiency and agile strategic follow-up. Dr. Gibson echoed this concern, suggesting that the disparity in investment amounts allocated to science and technology is a critical gap. He emphasized the urgent need for American capital to foster Japanese innovation further.

Why Invest in Japan Now?

Dr. Yamaguchi pointed out Japan’s strengths: world-class scientific prowess, genuine innovation, solid intellectual property, and possibilities for global partnerships—these elements form the competitive edge that attracts investment from around the globe. Dr. Gibson added that prominent U.S. pharmaceutical companies and biotech investors are actively seeking promising drug development assets due to challenges posed by patent expirations and their research and development hurdles. With governmental support in the biomedical field, investors' interest in Japan has increased significantly, further bolstered by the presence of international venture capital firms recognized by AMED (Japan Agency for Medical Research and Development).

The Global Standard: Why U.S. Investors Are Focusing on Japan

Dr. Yamaguchi reiterated Japan’s unique advantages, reinforcing that the country’s achievements in science position it as an essential investment opportunity. Dr. Gibson stated that for investment decisions, the emphasis lies heavily on novelty and innovation, identifying independently developed technologies that meet unmet medical needs as pivotal for generating significant value in the global market.

NANO Holdings: Bridging Japan and the World

Dr. Yamaguchi advocated for the creation of frameworks that connect Japan’s innovative assets to the global market. To actualize this vision, he outlined a four-pillar approach for fostering investments: discovering superior technologies, linking capital, designing value development, and creating exit strategies (such as partnerships, licensing, and M&As). Ongoing consultations with influential U.S. investors, coupled with alliances among global pharmaceutical enterprises, are part of the mission to present Japan's innovations to the world.

In summary, Dr. Gibson articulated that Nano Holdings aims to serve as a gateway, maximizing the value of Japanese science by creating business development opportunities and developing partnerships with multinational pharmaceutical companies—ultimately translating scientific advancements into effective medications accessible to patients worldwide.

Press Q&A Session Insights

During the subsequent Q&A session, participants engaged in discussions surrounding the right stages for Japan's technology to expand globally, challenges and solutions to connect Japan's drug development to international investment, and effective strategies for clinical development. Questions regarding the growth strategy of Nano Holdings also came up, reflecting strong interest in the company’s future directions.

Dr. Gibson explained that strategies for reconstructing Japanese assets may include establishing new companies or U.S. subsidiaries from existing Japanese firms. He stated that a variety of potential assets could arise from both publicly listed biotech companies and private firms, indicating a comprehensive hunt for promising opportunities.

Critical consensus emerged on the necessity of possessing promising human clinical data when attracting U.S. investments, particularly in fields with high unmet medical needs, such as autoimmune diseases and neurodegenerative disorders. The dialogue underscored the challenges of Japan's domestic market condition but emphasized that leveraging the global market for growth is essential for enhancing the value created by Japanese enterprises.

The event concluded on a note of optimism, with significant expectations surrounding Nano Holdings' future initiatives and the possibilities that lie ahead in connecting Japan’s scientific innovations to the broader international landscape.